Cullinan Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CGEM and other ETFs, options, and stocks.

About CGEM

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617.

CEO

Nadim Ahmed

CEONadim Ahmed

Employees

111

Employees111

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2016

Founded2016

Employees

111

Employees111

CGEM Key Statistics

Market cap

443.79M

Market cap443.79M

Price-Earnings ratio

-2.51

Price-Earnings ratio-2.51

Dividend yield

—

Dividend yield—

Average volume

263.65K

Average volume263.65K

High today

$7.93

High today$7.93

Low today

$7.52

Low today$7.52

Open price

$7.86

Open price$7.86

Volume

214.60K

Volume214.60K

52 Week high

$21.01

52 Week high$21.01

52 Week low

$6.85

52 Week low$6.85

Analyst ratings

100%

of 11 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own CGEM. This list is generated using Robinhood data, and it’s not a recommendation.

Cullinan Therapeutics

Why Robinhood?

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Show more

CGEM Key Statistics

Analyst ratings

100%

People also own

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617.